



Schweizerische Kopfweggesellschaft
Société Suisse des Céphalées
Società Svizzera di Cefalea
Societad Svizra da mal il Chau
Swiss Headache Society

Member of the

SFONS Swiss Federation of
Clinical Neuro-Societies



Program

Headache-Symposium 2022

Current Topics in Headache Care

November 24, 2022 | 13:00-18:00

CHUV Lausanne, Auditoire Mathias Mayor

headache2022.congress-imk.ch

HEADACHE-SYMPIOSIUM 2022

Dear colleagues,

On Thursday, November 24, 2022, the Swiss Headache Society SHS cordially invites you to the 14th Headache Symposium, which will take place at the Lausanne University Hospital CHUV, Auditoire Mathias Mayor in Lausanne.


The Scientific Committee has put together a multi-faceted and interesting program under the theme "Current Topics in Headache Care". The first session will deal in depth with the topic of Trauma and Headache, while the second session will focus on Cluster Headache and other TAC. We are delighted to welcome as keynote speakers for these sessions two internationally renowned experts, Dr. Henrik Winther Schydtz from Denmark and Dr. Anish Bahar from the United Kingdom.

In addition to the main sessions, we would also like to cordially invite you to our industry partners' symposium "What's new?". This symposium will take place for the first time in a new, lively format. There will also be room for poster presentations (one of which will be awarded by our committee) and informal social exchange.

Given the prevalence of headache disorders and the associated disease burden the program targets a large medical community ranging from neurologists and headache specialists to family physicians and other health care professionals involved in treating headache patients. We hope that across this range you will find the programme interesting and relevant and decide to join us for this event.

We are looking forward to welcoming you in Lausanne !

For the Swiss Headache Society



Prof. Andreas Kleinschmidt, MD
President of the Swiss Headache Society

www.headache.ch | kopfweh@imk.ch



Prof. Philippe Ryvlin, MD
Head of the Department of Clinical
Neuroscience (DNC)
Centre Hospitalier Universitaire Vaudois (CHUV)

GENERAL INFORMATION

Date Thursday, November 24, 2022

Congress venue Centre Hospitalier Universitaire Vaudois (CHUV)
Auditoire Mathias Mayor
Rue du Bugnon 21 | CH-1011 Lausanne

Congress website headache2022.congress-imk.ch

Language Slides and presentations in English

Credits Swiss Neurological Society (SNS): 4 Credits
Swiss Society of Neurosurgery (SSNS): 4 Credits
Swiss Society of General Internal Medicine (SSGIM): 3 Credits
Swiss Society of Neuropaediatrics (SSNP): 3 Credits

Registration / Fees Online via
headache2022.congress-imk.ch:

	Until October 26, 2022	From October 27, 2022
Members Swiss Headache Society	30	50
Non-member physicians	60	80

Fees in CHF

Cancellation policy All cancellations must be electronically mailed to **IMK**
Cancellations received up to October 26, 2022: 50% refund will be made
Cancellations received starting from October 27, 2022: no refund will be made

Confirmation of participation Attendants will receive an electronic confirmation of participation per e-mail after the symposium

Protection concept See congress website for current information

Website and contact SHS www.headache.ch | kopfweh@imk.ch

President of the SHS Prof. Andreas Kleinschmidt, MD, Geneva

Scientific committee Prof. Andreas Kleinschmidt, MD, Geneva | Chairman Scientific Committee
Gabrielle Di Virgilio, MD, Rennaz
Prof. Andreas R. Gantenbein, MD, Bad Zurzach
Prof. Christoph Schankin, MD, Berne
MER clin. Philippe Staeger, MD, Lausanne
Prof. Susanne Wegener, MD, Zurich

Professional Congress Organizer (PCO) **IMK** Institute for medicine and communication Ltd.
Harald F. Grossmann
Münsterberg 1 | CH-4001 Basel | Phone +41 61 561 53 53
www.imk.ch | congress@imk.ch

Main Sponsors



Sponsors



PROGRAM | THURSDAY, NOVEMBER 24, 2022

12:00-13:00

Registration

13:00-14:30

Session I: Trauma and Headache

Chair: Antonella Palla, Zurich

13:00-13:05

Welcome

Antonella Palla, Zurich

13:05-13:50

Keynote: Post-traumatic headache

Henrik Winther Schytz, Glostrup, DK

13:50-14:15

Headache after head trauma: neuropsychiatric perspectives over the lifespan

Katrin Rauen, Zurich

14:15-14:30

Tricky Trauma Case

Stephan Ulmer, Feldmeilen

Commented by Henrik Winther Schytz

14:30-14:35

Coffee Break | Exhibition

14:35-15:35

Industry Flash Session

What's new?

Moderation: Andreas R. Gantenbein, Bad Zurzach

14:35-14:50

Switching between aCGRP mAbs - Real-World

Update at its FINESSEt

Christoph Schankin, Berne

mepha  |  teva

14:50-15:05

Time to press pause: First prospective Swiss real-world data of the impact of a temporary interruption of a CGRP treatment (erenumab)

Chiara Zecca, Lugano

 NOVARTIS

15:05-15:20

Eptinezumab for the preventive treatment of migraines - Clinical evidence and practical considerations

Gabrielle Di Virgilio, Rennaz

 Lundbeck
COMPETENCE IN CARE

15:20-15:35

Galcanezumab helps address patients unmet needs in migraine prevention

Athina Papadopoulou, Basel

 Lilly

15:35-15:40

Coffee Break | Exhibition

PROGRAM | THURSDAY, NOVEMBER 24, 2022

15:40-17:10

Session II: Cluster Headache and other TAC

Chair: Andreas Kleinschmidt, Geneva

15:40-16:25

Keynote: Cluster Headache

Anish Bahra, London, UK

16:25-16:50

Launching a Swiss TAC Headache registry

Heiko Pohl, Zurich

16:50-17:05

Tricky TAC Case

Antonia Klein, Berne

Commented by Anish Bahra

17:05-17:10

Closure & Farewell

Andreas Kleinschmidt, Geneva

from 17:10

Apéro | Exhibition

INVITED SPEAKERS & CHAIRS

Anish Bahra, FRCP, MD

National Hospital for Neurology and
Neurosurgery and Whipps Cross Hospital,
Barts Health NHS Trust,
Department of Neurology, London, UK

Antonia Klein, MD

Inselspital, Universitätsspital Bern,
Universitätsklinik für Neurologie, Bern

Prof. Andreas Kleinschmidt, MD

Hôpitaux Universitaires de Genève,
Service de neurologie, Genève

PD Antonella Palla, MD

Schulthess Klinik Zürich,
Swiss Concussion Center, Zürich

Heiko Pohl, MD

Universitätsspital Zürich,
Klinik für Neurologie, Zürich

Katrin Rauen, MD, FEBN

Psychiatrische Universitätsklinik Zürich,
Zentrum für Alterspsychiatrische Versorgung,
Zürich

Prof. Stephan Ulmer, MD


neurorad.ch, Neuroradiologie, Feldmeilen

Henrik Winther Schytz, MD, PhD, DMSci

Ringshospitalet, Danish Headache Center,
Department of Neurology and
The Neuroscience Center and
University of Copenhagen, Glostrup, DK

TRAVEL INFORMATION

- 1 Centre Hospitalier Universitaire
Vaudois (CHUV)
Auditoire Mathias Mayor (BH08)
Rue du Bugnon 21
CH-1011 Lausanne



Arriving by plane Geneva Airport (GVA) is the closest airport to Lausanne. Direct trains from Geneva Airport to Lausanne are available around four times per hour, with traveling times of around 50 minutes. Zurich Airport (ZRH) also offers relatively easy access to Lausanne. Direct trains from Zurich Airport to Lausanne take around 2h30.

Arriving by train Longer distance trains to Lausanne are available from Geneva, Berne, Zurich, Zurich Airport, St.Gallen, Lucerne, and Basel (usually with transfer in Berne or Biel), as well as from Paris (France) and Milan (Italy).

Arriving by Lausanne public transport There are 3 ways to get from Lausanne train station to CHUV: either by subway, taxi or foot. By subway: take the M2 line, with a traveling time of 10 minutes (costs: CHF 4.-).

Arriving by car Parking possibilities around the Cité hospitalière du Bugnon are limited. The only parking possibility inside the hospital city is the parking of the Hospitals S.A. (with 493 paying places, open 24 hours a day). Location: Avenue de Beaumont 25, Lausanne.

First Announcement



SCHWEIZERISCHE GESELLSCHAFT FÜR NEUROCHIRURGIE
SOCIÉTÉ SUISSE DE NEUROCHIRURGIE
SOCIETÀ SVIZZERA DI NEUROCHIRURGIA
SWISS SOCIETY OF NEUROSURGERY

www.swissneurosurgery.ch

Gemeinsame Jahrestagung 2023

Schweizerische Neurologische Gesellschaft
Schweizerische Gesellschaft für Neurochirurgie

Gastgesellschaft:

Schweizerische Gesellschaft für Verhaltensneurologie

Réunion Annuelle Conjointe 2023

Société Suisse de Neurologie
Société Suisse de Neurochirurgie

Société Invitée:

Société Suisse de Neurologie Comportementale

23.-24. November 2023

Kongresshaus Zürich

Organized by **IMK** Institut für Medizin und Kommunikation AG

3. Neurologisches Pflegesymposium
3^{ème} Symposium neurologique en soins

AJOVY[®]
(Frémanezumab)
Solution injectable 225 mg



A LIFE IN MOTION BEGINS WITH LESS MIGRAINE™

L'anticorps de CGRP pour la prophylaxie **spécifique** de la migraine¹

- Schéma posologique flexible: **1x par mois** ou **4x par an**¹
- Comme stylo prérempli ou seringue préremplie¹
- Agit rapidement¹ et durablement²
- Profil de tolérance similaire à celui du placebo³⁻⁵

teva

Vous trouverez des informations sur le remboursement par les caisses maladie (limitatio) sous www.spezialtaetenliste.ch

CGRP: Calcitonin Gene-Related Peptide

1. Information professionnelle d'AJOVY[®], www.swissmedicinfo.ch. **2.** Goadsby PJ et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. *Neurology* 2020; 95:e2487-2499. **3.** Silberstein SD et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. *N Engl J Med* 2017; 377(22): 2113-2122. **4.** Dodick DW et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. *JAMA* 2018; 319(19): 1999-2008. **5.** Ferrari MD et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet* 2019; 394:1030-40.

AJOVY[®]

C: 1 seringue préremplie contient 225mg de frémanezumab dans 1.5ml de solution (150mg/ml). 1 stylo prérempli contient 225mg de frémanezumab dans 1.5ml de solution (150mg/ml). **I:** Traitement prophylactique de la migraine chez l'adulte, en cas d'indication. **P:** 225mg une fois par mois ou 675mg tous les trois mois. Instructions posologiques particulières, voir l'information professionnelle. **Ci:** Hypersensibilité au principe actif ou à l'un des excipients. **PC:** Réactions d'hypersensibilité, telles que rash, prurit, urticaire et gonflements, syndrome de Stevens-Johnson, affections cardiovasculaires graves. Enfants et adolescents de moins de 18 ans. Le stylo prérempli contient 0.025mg de sodium pour 1.5ml. **G/A:** Ne doit pas être utilisé pendant la grossesse, sauf en cas de nécessité absolue. Envisager une utilisation pendant l'allaitement uniquement en cas de besoin clinique. **EI:** Très fréquents: douleurs, induration, érythème. Fréquents: prurit. **IA:** N'est pas métabolisé par les enzymes du cytochrome P450. Aucune étude clinique n'a été réalisée. **Liste:** B. Pour des informations complémentaires sur le médicament consulter www.swissmedicinfo.ch [2421]